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1 Introduction
Health care costs have risen faster than the rate of economic growth in all OECD countries
and this is projected to continue as a result of new medical technology, rising expectations
and the increasing needs of the ageing population (OECD, 2015). In Britain, about 10%
of GDP is spent on the National Health Service (NHS), which is broadly in line with other
European counties. That proportion has doubled since the establishment of the NHS in 1948
(Charlesworth and Bloor, 2018). In this policy setting, it is important for policymakers to
be able to identify the sections of the population where costs are high and rising, to establish
priorities for resource planning and preventive policy.
Some recent studies have used administrative data from Spain, the UK and the Nether-
lands (Brilleman et al., 2014; Carreras et al., 2018; De Meijer et al., 2011; Howdon and
Rice, 2018) to examine the “red herring” thesis (Zweifel et al., 1999). This suggests that
extrapolation of simple age-health expenditure curves may not yield an accurate picture
of current and future healthcare expenditures, which are primarily driven by proximity to
death rather than age itself, with proximity to death in turn driven by health and disability
status. In a similar context, Dalgaard and Strulik (2014), drawing on research in biology
and medicine to develop an economic model of aging, argued that age of death is determined
by optimal health investments and is relevant to biological aging; chronological aging and
death are inevitable but individuals typically invest in their health, which slows down aging
and prolongs life.
However, proximity to death is unobserved prior to death and therefore of no practical
use for projecting health care expenditure for the needs of health policy. The development of
forward-looking policy to control utilisation of healthcare services and the subsequent costs
cannot be done solely on the basis of records accumulated by healthcare systems, since those
records do not contain information about the full range of personal and socioeconomic char-
acteristics that may be required to account for confounding effects and do not have adequate
coverage of individuals with latent health conditions that have not yet reached the stage
of diagnosis. Analysis aiming to characterise individuals at risk of generating an increased
burden on the healthcare system and identify potential cost savings requires data from the
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general population. Most relevant existing studies (Brilleman et al., 2014; Carreras et al.,
2018; De Meijer et al., 2011; Howdon and Rice, 2018), although emphasising the importance
of the current morbidity profile of the population for current healthcare spending, have not
been able to identify individuals within the ‘apparently healthy’ population, who are never-
theless at risk of high future rates of healthcare utilisation and cost. The ability to do this
would allow detailed targeting of health interventions, with the prospect of significant cost
savings. A cumulative biological measure of wear and tear on the body may be particularly
valuable as a proxy for future health risks.
The potential scope for prevention strategies to reduce health risks and contain healthcare
costs has been central to health policy debates worldwide (Cohen et al., 2008) but the
evidence for their effectiveness so far is mixed (Russell, 2009). Chernew and Newhouse (2011)
argued that better targeting of preventative health services to high-risk groups is needed to
ensure substantial cost savings for prevention strategies, otherwise potential cost savings tend
to be offset by the high cost of unnecessary additional services offered to those with no need.
This argues for more research characterising at-risk population groups – especially those not
currently visible to the healthcare system – to target potential interventions effectively.
Using data from the UK Household Panel Study (UKHLS, also known as Understanding
Society), the key feature of our empirical modelling is the use of biomarkers to predict
subsequent healthcare utilisation. UKHLS collects information on utilisation counts for the
numbers of general practitioner (GP) and outpatient/day-patient (OP) consultations, and
the number of days spent as a hospital inpatient (IP) within the preceding twelve months.
Financial costs provide a natural metric for combining these different aspects of resource
utilisation into an overall measure of the burden on the public healthcare system. We use
data combination techniques to incorporate administrative data for England on GP, OP and
IP utilisation and official reference costs to estimate the excess public costs generated by
those with elevated biomarkers at baseline. By excluding individuals who reported any past
or recently diagnosed long-lasting health condition, we focus on individuals who appeared,
from a clinical point of view, to be healthy at baseline and who would not therefore already
be prioritised by the healthcare system. To the best of our knowledge, our analysis is the
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first of its kind.
Our main contribution is to show the power of biomarker data at baseline for predict-
ing future health service utilisation and concomitant future costs. Use of a long (five-year)
prediction horizon is important, since public health initiatives and resource planning are not
short-term processes. The biomarkers we use for prediction are more objective health mea-
sures than conventional self-reported or self-assessed health (Biomarkers Definitions Working
Group, 2001), and several epidemiological studies have argued that biomarkers can predict
future health and mortality risks even in the case of individuals without history of ill health
(Goldman et al., 2006; Glei et al., 2014; Zethelius et al., 2008; Wang et al., 2006). Biomarkers
may provide direct information on pre-disease pathways, in particular by measuring phys-
iological processes that are below the individual’s threshold of perception (McDade et al.,
2007). However, these epidemiological studies have not considered cost implications explic-
itly and it is possible that the implications of health for future social costs and utilisation
of healthcare services are quite different from their implications for any medical measure
of health outcome. In this study, we use a measure of cumulative biological risk factors,
often called allostatic load, which is an index combining biomarkers relevant to different
biological systems, to give an overall assessment of physical health (Davillas and Pudney,
2017; Howard and Sparks, 2016; Seeman et al., 2004). The objective nature of biomarkers is
also important for the design of targeted interventions; unlike self-assessed and self-reported
health measures, biomarkers cannot normally be manipulated to achieve a desired outcome
of the screening process and, thus, they prevent ‘gaming’ of the screening process.
We develop a data combination method to incorporate administrative data on caseload
composition and unit costs in circumstances where administrative data matching at the
level of the survey respondent is not feasible. Comprehensive individual-level administrative
healthcare data are non-existent in many countries and, even where they do exist, there
are legal and ethical data security difficulties that typically prevent matching to suitable
longitudinal surveys.1 A further difficulty is that individual-level matching of survey data
1For example, in the USA, relevant administrative data are typically based on claims for a selection of
insurance providers and do not usually represent total costs given co-payments (Riley, 2009) and, although the
Medical Expenditure Panel Survey contains data on health care costs, it lacks objective health measures and
baseline health status, including pre-symptomatic and pre-diagnosed conditions. The UK has no national-
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and administrative records normally requires informed consent, generating a possible source
of bias (Ja¨ckle et al., 2018; Riley, 2009). In our application, we attach average unit costs to
GP and OP consultation counts, but use a more sophisticated data combination method for
assigning expected costs to the predictions of the IP utilisation model, using individual-level
survey information (on age, gender and duration of hospital stays) combined with admin-
istrative data aggregated within broad treatment/demographic patient groups. In applying
the data combination method, we overcome some difficulties in the survey observation of
healthcare utilisation, which yields count variables with highly skewed distributions featur-
ing an excess mass of zero observations (Van Doorslaer et al., 2004) and counts observed
within intervals rather than as exact figures. We use a zero-inflated interval-observed negative
binomial specification, tailored to the form of the UKHLS data, together with appropriate
prediction and simulation methods for conducting post-estimation analysis.2
It is beyond the scope of this paper to assess the cost-effectiveness of any particular
screening or prevention strategies, but our results have potential implications for health pol-
icy in the UK and beyond. They can be used to indicate priority areas for interventions (such
as screening programmes and health education initiatives) to control future treatment costs
among individuals who have not yet reached the stage of diagnosis. Our analysis provides
general evidence on the pattern of risk of future excess healthcare costs that is relevant to
the many countries with healthcare systems similar to the UK (i.e., mostly publicly funded).
These results contribute to the policy debate on the effectiveness of prevention strategies
(WHO, 2018), and suggest that targeting interventions to reduce future costs may require
more regular collection of biomarkers at a wider population level than is usual at present.
For example, the NHS England Health Check offers only quinquennial check-ups, including
blood tests (Schulein et al., 2017), to the 40-74 age group, and take-up (around 20%) is
low. However, similar health checks in Japan are successfully offered annually to full-time
employees and the 40-74 age group (OECD (2019), chapter 3). Of course, implementing a
scale, individual-level administrative datasets on GP and community health service delivery; hospital episode
statistics data have been linked to the Millennium Cohort Study but that is limited to a single birth cohort
of pre-mature individuals.
2In these circumstances, some researchers have either used non-discrete interval regression models (Brown
et al., 2015) or have sacrificed information by transforming outcomes into binary variables (Allin et al., 2011).
There have been few applications of the more natural grouped count data models (but see Fu et al. (2018)
for a Poisson-based example).
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high-frequency, universal check-up programme is costly but it may be cost-effective if sub-
stantial future healthcare costs come from the apparently healthy part of the population.
This is related to the prevention paradox of the epidemiology literature (Attwood et al.,
2016), where the majority of cases of a disease may come from people at moderate risk of
that disease, and only a minority from people at high risk of the disease.
Our results are also relevant to the design of capitation fee systems. Beyond the UK, cap-
itation payment schemes are used in several European countries, New Zealand and Canada
(Brilleman et al., 2014; Chambers, 1998; Sibley and Glazier, 2012; Shepherd, 2017), where
they are used to pay providers prospectively for the treatment of patients to whom they
are contracted to provide healthcare. There is a need to tailor capitation payments closely
to expected future healthcare costs to reduce incentives for providers to engage in “cream-
skimming” behaviour. Currently, most capitation payments are not based on patient-level
data, apart from age and gender, neglecting other potentially important patient-level char-
acteristics (Brilleman et al., 2014).
2 Data: the Understanding Society panel (UKHLS)
The UKHLS is a longitudinal, nationally representative study of the UK, designed as a two-
stage stratified random sample of the general population. We use the Great Britain (GB)
subsample, excluding the Northern Ireland component of the UKHLS which does not provide
biomarker data. As part of wave 2 (2010-2011), nurse-measured and non-fasted blood-based
biomarkers were collected, giving a potential pool of 6,337 survey respondents with valid
data on all the nurse-collected and blood-based biomarkers used in our analysis. From those,
4,759 individuals had non-missing data on socioeconomic status and demographic covariates
at baseline (wave 2) and were successfully followed up at wave 7, when healthcare utilisation
measures are collected. Our focus is on individuals who appeared (from the viewpoint of
clinical diagnosis) to be healthy at baseline, so we further excluded from our analysis those
who reported any past diagnosis of a long-lasting health condition (asthma, chronic bronchi-
tis, congestive heart failure, coronary heart disease, heart attack or myocardial infarction,
stroke, cancer or malignancy, diabetes, high blood pressure, arthritis and liver condition), or
5
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a hospital inpatient stay with a newly diagnosed health condition. This allows us to follow a
set of 2,314 respondents in apparently good health at baseline, to a horizon up to five years
later.
2.1 A multi-system measure of health risks at baseline
Allostatic load was developed as a measure of biological risk arising from the cumulated
effects of chronic exposure to physical, psychosocial and environmental stressors that may
lead to physiological dysregulation and elevated risk of chronic conditions such as cardiovas-
cular disease, impaired lung and liver functioning. (Howard and Sparks, 2016; Seeman et al.,
2004). Allostatic load is a multisystem risk score, sensitive to morbidities that may be yet
undiagnosed (Geronimus et al., 2006; Turner et al., 2016). It captures chronic physiological
responses and dysregulations relevant to long-term chronic morbidity burdens, rather than
acute infections. Thus the predictive power of our allostatic load measure relates more to
healthcare demands arising from these chronic physical conditions, rather than those linked
to transient infections, accidental injury, mental ill-health, etc.
A large set of physical measurements and blood-based biomarkers, spanning multiple
dimensions of health, were collected by trained nurses at UKHLS wave 2. Our index combines
markers for adiposity, blood pressure, heart rate, lung function, inflammation, blood sugar
levels, cholesterol levels, liver function and steroid hormone.3
We use waist-to-height ratio to measure adiposity and resting heart rate (HR), systolic
blood pressure (SBP) and high-density lipoprotein cholesterol (HDL) to measure cardiovas-
cular health.4 Lung function is measured using a spirometer as forced vital capacity (FVC),
the total amount of air forcibly blown out after a full inspiration; higher FVC values indicate
better lung functioning. C-reactive protein (CRP) is our inflammatory biomarker, which rises
3Some authors include cortisol, in addition to the stress-related hormone dihydroepiandrosterone sulphate
(DHEAS), to capture primary responses to stress. However, cortisol is excluded here because of time-of-day
and other measurement difficulties in the UKHLS context. Similar constructions to ours have been used
extensively in previous studies (Davillas and Pudney, 2017; Howard and Sparks, 2016; Vie et al., 2014).
4SBP is the maximum pressure in an artery at the moment when the heart is pumping blood; it is
generally considered more relevant to health risks than diastolic blood pressure (Haider et al., 2003). Low
HDL cholesterol levels are associated with increased cardiovascular risks, while low HR and SBP indicate
lower risks.
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as part of the immune response to infection and is associated with general chronic or sys-
temic inflammation (Emerging Risk Factors Collaboration, 2010).5 Glycated haemoglobin
(HbA1c) is our blood sugar biomarker, and is a validated diagnostic test for diabetes. Al-
bumin is used to proxy liver functioning, with low albumin levels suggesting impaired liver
function. We also use dihydroepiandrosterone sulphate (DHEAS), a steroid hormone in
the body, representing one of the primary mechanisms through which psychosocial stressors
may affect health, with low levels associated with cardiovascular risk and all-cause mortality
(Ohlsson et al., 2010). We calculated a composite risk score measure to proxy allostatic load
after converting HDL, Albumin and DHEAS to negative values to reflect ill-health rather
than good health, and then transforming each of the nine biomarkers into a z-score and sum-
ming to produce the composite measure. The index is then scaled so that a 1-unit increase
in allostatic load corresponds to an increase of one standard deviation.6
To illustrate the magnitudes involved, consider a healthy woman with waist 79cm and
average height 162cm, normal systolic blood pressure of 105mmHg, heart rate 70bpm, an
average HDL cholesterol level of 1.6 mmol/L, and average values for other biomarkers. If
we compare her with a less healthy woman with waist 88, systolic blood pressure 140, heart
rate 90 and low HDL cholesterol 1.0, then the difference in allostatic load between the two
women is 1.5 standard deviations.7
2.2 Health care utilisation measures
Retrospective information was also collected at UKHLS wave 7, on the numbers of: GP
consultations; attendances at a hospital or clinic as an out-patient or day patient (OP); and
hospital in-patient (IP) days in the 12 months prior to interview. The GP and OP counts
were recorded in five categories (0, 1-2, 3-5, 6-10, more than 10), whereas respondents were
asked for the exact number of days spent in a hospital or clinic as an IP in the same period.
5We follow common practice by excluding cases with CRP values over 10mg/L because such values
normally reflect acute rather than systemic inflammatory processes (Pearson et al., 2003).
6When used singly in econometric models, each of these biomarkers has a statistically significant coef-
ficient, but their strong intercorrelations make it impossible to estimate robust models involving all nine
biomarkers jointly as covariates.
7The equivalent comparison for men of average height 175cm would involve waist measurements of 93cm
and 102.
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We excluded women who reported any in-patient days for childbirth during this period (about
0.5 per cent of our sample), so our cost analysis excludes services related to childbirth.
There are clear demographic differences in utilisation. Figure 1 shows gender differences
in the distributions of GP and OP consultations, indicating that women tend to seek care
from GP or OP consultations more frequently than men. GP and OP consultations are also
more frequent among older people (Appendix Figures A1 and A2).
Figure 1: Distribution of the numbers of GP and OP consultations in the preceding 12
months by gender
The GP, IP, and OP utilisation counts are retrospective self-reports of utilisation of health
services over the past year, so they are potentially subject to reporting errors and possibly
biases in long-term recall (Bound et al., 2001). A fundamental difficulty in assessing the
prevalence and nature of survey errors is the absence of an accurate external measure to val-
idate the survey responses.8 Matched individual-level data on health service utilisation are
not available to us, but we can compare the full wave 7 UKHLS data with external sources of
information (Hobbs et al., 2016; ISD Scotland, 2017; NHS Digital, 2017; NHS Improvement,
2017). Appendix Tables A1 and A2 give comparisons of GP and OP consultation data for
England and Scotland and IP days for England only. These comparisons are not straight-
forward, since the UKHLS GP and OP data are interpolated, there are minor differences
in timing, and the administrative data relate to the whole population whereas the UKHLS
8See Meyer and Mittag (2019) for the use of validation data in the context of income.
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is a sample from the household population, subject to variations in response rates across
population groups.9
Overall, we find that the administrative GP consultation rates for England and Scotland
are reasonably close to mean counts interpolated10 from the UKHLS interval data (Table A1).
There is some evidence of moderate under-reporting in the UKHLS, with discrepancies larger
for women than men, for older than younger respondents and for the English rather than
Scottish subsample. For OP consultations (Table A2) we have no demographic breakdown
of the administrative data; the overall mean counts are reasonably close to the ratio of
aggregate consultations to relevant population size, for both England and Scotland (UKHLS
rates lower by 4% and 12% respectively). For IP utilisation, we only have administrative data
for England. Unlike most of the comparisons for GP and OP consultations, the UKHLS mean
IP count is larger (by almost 10%) than the corresponding administrative estimate (Table
A2), but this is largely due to definitional differences – an IP episode completed within one
day is recorded as a zero-days duration in the HES data, but would generally be reported
by UKHLS respondents as a one-day episode. When linking costs to durations (section 5)
we allow for this by adding 1 to durations in the HES data.
These differences should be borne in mind when interpreting our results, but do not
seem large enough to greatly distort econometric results. The main cause for concern is the
possible under-reporting of GP consultations by older women, which would suggest that the
large demographic effects reported in Tables 2-4 may be underestimates.
2.3 Costs
Financial cost is the natural metric for distilling the three categories of resource use into a
single measure of burden on public healthcare resources. However, this is not straightforward
9The comparisons presented in the appendix use unweighted UKHLS data. Since the UKHLS response
weights are built up sequentially over waves, missing data causes progressive loss of information and, by wave
7 almost a quarter of individuals have zero weights. If we use the official weights, results are not changed in
any important way from those presented in Tables A1 and A2.
10Interpolation is done here by fitting negative binomial distributions (with zero-inflation where appro-
priate) to the interval data, then calculating the expected value of the count conditional on the observed
interval.
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because the UKHLS interview gives no details of the types of treatment involved, nor is it
possible to match survey respondents to records of the public healthcare system.11 Instead,
we pursue a data combination strategy, exploiting average cost data published in varying
detail for the GP, OP and IP resource classes.12 For simplicity, we use reference costs
and caseload composition figures from NHS England for the whole of the UKHLS sample,
including the relatively small Scottish and Welsh subsamples (making up 5% and 2% of the
analysis sample respectively). Robustness checks reported in section 6 confirm that results
are not materially affected by restricting the sample to respondents resident in England.
GPs are the gatekeepers to NHS healthcare services but they are self-employed contractors
rather than employees of the NHS and, consequently, financial data relating to GP services
are not available on the same detailed basis as for the rest of the NHS. We use the mean
unit cost per consultation estimated by Curtis and Burns (2017) as £66.20 per consultation,
comprising £37 for GP costs and £29.20 for associated prescription costs (on a net ingredient
cost basis).
NHS reference cost data for OP and IP activity in England give unit costs broken down in
great detail by type of treatment and compiled according to standard measurement conven-
tions (Department of Health, 2016). We use the national schedules of reference costs (NHS
Improvement, 2017), providing data on average unit cost for each service submitted by the
NHS providers in 2016/17, a similar period to that covered by UKHLS wave 7. For OP cases,
the average unit cost and aggregate number of attendances in each treatment category relate
to both outpatient and day-case visits. After excluding paediatric categories which are not
relevant to UKHLS adult respondents, maternity services and categories with fewer than 50
cases in the year, we are left with 1,355 treatment categories with an average caseload of
55,704 attendances per category and a mean (caseload-weighted) unit cost of £163.32 per
OP consultation.13
11Consents for matching of UKHLS data to hospital episodes administrative data were obtained for a subset
of UKHLS respondents, but a usable matched dataset is not expected to be available for a considerable time.
Moreover, such a dataset would not cover GP consultations and would raise significant issues of non-consent
bias.
12GP, OP and IP costs are only part of the cost picture. The UKHLS questions do not cover resources
like community nursing, ambulance services, etc. Moreover published hospital reference costs exclude some
activities such as screening (Department of Health (2016), section 15).
13Unlike the reference administrative IP costs data, which are classified by duration of hospital stay, the
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For IP cases, reference costs relate to episodes of care, defined as “the time spent under
the care of one consultant”, are available as average unit cost by groups of patient events
that have been judged to consume a similar level of resource, known as Healthcare Resource
Groups (HRG), along with the aggregate number of HRG episodes (NHS Improvement,
2017). Elective and non-elective IP treatment are separated in the official activity and
cost data, and we treat them as distinct treatment types. Treatment categories are further
separated into elective (E), non-elective long stay (NEL) and non-elective short stay defined
as 2 days or less (NES). E and NEL episodes are further split to allow for excess bed days:
health providers are required to provide per diem costs for the part of longer admissions
that go beyond a ‘trim point’ set for each HRG. In our analysis, we treat E, NEL and NES
episodes as separate categories within each HRG, exploiting the fact that caseload, unit cost
and mean length of stay (but not other episode characteristics) are broken down by type
of episode (NHS Digital, 2017; NHS Improvement, 2017). After excluding irrelevant and
negligible categories and those with missing or invalid unit cost or mean stay data, we are
left with 3,827 IP categories, with a (caseload-weighted) mean stay length of 3.5 days, and
a mean total of case-days of 9,184 per category. The overall mean daily unit cost defined
as the ratio of aggregate cost to aggregate number of days IP treatment is £542 per day.
It should be borne in mind that these figures relate to all adult in-patients (thus excluding
non-patients with zero costs), whereas our analysis of UKHLS survey data is concerned with
average costs for the population of people with no diagnosed conditions at baseline, who
are likely to have lower (and possibly zero) rates of healthcare utilisation than the average
patient. Thus, our predicted costs are expected to be smaller than simple averages estimated
from administrative data on patients as a whole. Descriptive statistics of the variables used
in our analysis are presented in Table A3 of the Appendix.
available unit cost data for GP and OP consultations is not classified by frequency. It is possible that
patients who experience more complications more frequently may impose a higher GP and OP cost at each
consultation than the average for those health services. Therefore, our analysis may under-predict GP and
OP costs for such individuals and over-predict them for individuals with low-cost characteristics. If so, our
estimates would give a lower bound for the gradient of future costs with respect to baseline health and other
characteristics. If this bias exists at all, our focus on the population group who are apparently disease-free
at baseline is likely to moderate its extent.
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3 Grouped count data models of healthcare utilisation
Let Yi C 0 be the ith observation on a dependent variable (the GP, OP or IP utilisation
count), which takes non-negative integer values, and X i a vector containing the explanatory
covariates. We allow for the possibility of zero-inflation: a or mixture process, where some
individuals have a degenerate zero count with probability 1, while others have a count drawn
from a standard distribution. The probability of a degenerate zero is specified as probit:14
Prdegenerate 0SX i   ΦX i1γ (1)
where X i1 is a subvector of X i.
The distribution of Y among the non-degenerate population is gySX i2, where X i2 is
another subvector of X i. The mixture distribution of Y is:
fySX i  
¢¨¨¨¨
¦¨¨¨¨
¨¨¤
ΦX i1γ  1 ΦX i1γg0SX i2 if y   0
1 ΦX i1γgySX i2 if y A 0
(2)
Our observations are not necessarily on Yi itself but rather an interval within which Yi
lies. Consequently, we have a pair of observed dependent variables,  Li, Ui with the property
that Li B Yi B Ui. For the GP and OP consultation counts, the observable limit pairs are in
the set 0,0, 1,2, 3,5, 6,10, 11,ª; for the IP count we have exact observation, so
Li   Yi   Ui. The likelihood for individual i is the conditional probability of observing the
event Li B Yi B Ui:
PrLi B Yi B UiSX i   UiQ
y Li
fySX i (3)
The model is completed by specifying a parameterised functional form for the non-
degenerate component distribution g.SX i. We initially considered three alternative base
models, binomial, Poisson and negative binomial (NB). The NB specification gave by far the
best fit in every case (Pudney, 2019). It is derivable as a Poissonλiν-gammaα1, α mix-
ture, where λi   eX i2β and lnα is treated as an unrestricted constant parameter. This gives
14We also estimated logit specifications which gave almost identical estimates.
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a distribution for y with mean λi and variance 1 αλi.15 The ML estimator is implemented
using a Stata command intcount (Pudney, 2019).16
4 Parameter estimates
The explanatory covariates X used in our healthcare utilisation model represent individual
characteristics that have been shown to affect health outcomes directly or indirectly (Davil-
las and Pudney, 2020; Carrieri and Jones, 2017; Van Doorslaer et al., 2004). They were
collected as part of the UKHLS wave 2 main survey, along with our biomarker measures.
We use two indicators of socioeconomic status. Educational attainment is represented as a
3-category classification: degree-equivalent (reference category), intermediate, and no/basic
qualification. Household income is the sum of the gross incomes of all household members
but, to avoid spurious correlation arising from the fact that disability resulting from ill-health
creates eligibility for disability benefits (Morciano et al., 2015), income from those sources
is excluded. We allow for differences in household composition by equivalising household
income using the modified OECD equivalence scale before using a log transformation to al-
low for the concavity of the health-income association. A flexible quadratic function of age
and gender is used to capture demographic differences. Age is measured in decades from an
origin of 50 years, to reduce its scale and the correlation between the linear and quadratic
term, to improve numerical conditioning of the likelihood function. The transformation of
age has no effect on the predictions nor the coefficient and standard error of the quadratic
coefficient. Finally, we also allow for differences between the three nations of Great Britain
(England as the reference category and Scotland and Wales), since NHS policy is determined
on a national basis.17 The demographic and socioeconomic covariates are included in the
15In the terminology of Cameron and Trivedi (2013), this is the NB2 parameterisation of the regression
model. Interval versions of the Poisson model (Dickman et al., 2004) and its zero-inflated version (Fu et al.,
2018) have been used before, but we are not aware of any previous application of a zero-inflated negative
binomial model under interval observation.
16This is a quite standard application of maximum likelihood, but see Fu et al. (2018) for a detailed
discussion of the asymptotic properties in the more special Poisson case.
17We used initially a larger set of covariates than that shown in Table 1, including additionally urban/rural
area type, marital status, housing tenure and household size. We dropped covariates only where their coeffi-
cients were statistically insignificant at the 10% level in all models, resulting in the smaller set of covariates
listed in Table 1. To curtail pre-test bias, we retained the remaining covariates in all models, irrespective
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healthcare utilisation models to allow us to assess the predictive power of allostatic load net
of the potential confounding effect of individuals’ demographic characteristics and socioe-
conomic status. They may proxy a wide range of socioeconomic factors and, thus, do not
necessarily have a simple direct causal interpretation.
In implementing the NB models, we embed an important feature of the healthcare system
in the UK. GPs normally act as gatekeepers to the hospital system, so OP or IP episodes are
mostly preceded by GP consultations (Van Doorslaer et al., 2004; Brilleman et al., 2014).
For that reason, we model OP and IP utilisation counts conditional on the number of GP
consultations, with X extended to include categorical indicators of the number of GP con-
sultations. Parameter estimates for our preferred models are shown in Table 1 (columns 2,
4 and 6). Marginal OP and IP models, estimated without conditioning on the GP consul-
tation count, are also shown for comparison (columns 3 and 5). For the OP and IP counts,
the best-fitting model involves zero-inflation, distinguishing between individuals with zero
and non-zero GP consultation counts. The estimated impact of a zero GP count on the OP
and IP counts is almost completely sharp, with large negative intercept and large positive
coefficient. That implies negligible zero-inflation for the OP and IP counts if the GP count
is positive, and large probabilities of a degenerate zero (0.69 for the OP count and 0.98 for
the IP count) if the GP count is zero.18
of statistical significance in particular models. Inclusion of smoking and physical activity produced no sig-
nificant effects in any model after accounting for allostatic load, indicating that information on unhealthy
lifestyles at baseline has no additional predictive power for subsequent health care utilisation beyond what
can be achieved using biomarkers.
18In practice the gatekeeper role of GPs is not completely sharp, since GP consultations leading to an OP
consultation or IP episode may not fall in the same 12-month recall period; also some emergency IP cases may
reach hospital without GP involvement. Consequently we have chosen to leave the model fully parameterised
rather than imposing a zero probability of zero-inflation when the GP count is zero. For zero-inflated models
of the GP count, the ML optimisation always led to corner solutions where the probability of a degenerate
zero count was essentially zero. Demographic and socioeconomic covariates were not significantly significant
in the zero-inflation probit component of the conditional models for OP and IP.
14
J
urn
al 
Pr
-pr
oo
f
Table 1: Estimated parameters for grouped negative binomial models of GP, OP and IP
utilisation: baseline demographic, socioeconomic and health state coefficients
OP model IP model
GP marginal conditional marginal conditional
Parameter (1) (2) (3) (4) (5)
Allostatic load 0.210*** 0.129** -0.030 0.555*** 0.219
(0.036) (0.053) (0.055) (0.162) (0.175)
§Age -0.053* 0.033 0.068 0.241 0.177
(0.030) (0.046) (0.045) (0.154) (0.137)
§Age2 0.017 0.018 0.002 -0.024 -0.051
(0.016) (0.026) (0.026) (0.081) (0.072)
Male -0.198*** -0.327*** -0.319*** -0.285 -0.493
(0.076) (0.121) (0.110) (0.397) (0.370)
§Age  male 0.146*** 0.187*** 0.119* -0.367* -0.165
(0.042) (0.069) (0.067) (0.209) (0.201)
§Age2 male -0.025 0.024 0.061* 0.182 0.247**
(0.025) (0.038) (0.037) (0.117) (0.111)
 No qualifications 0.092 0.033 -0.016 0.744 1.481**
(0.092) (0.142) (0.137) (0.566) (0.718)
 Intermediate qualifications 0.016 0.104 0.112 0.691** 0.745**
(0.065) (0.103) (0.096) (0.321) (0.290)
ln(income) -0.140*** -0.106* -0.002 -0.209 0.101
(0.045) (0.062) (0.059) (0.237) (0.206)
¶ Wales 0.555*** 0.140 -0.365 -0.061 -1.062*
(0.192) (0.332) (0.249) (0.694) (0.590)
¶ Scotland -0.018 -0.246 -0.311 0.278 -0.405
(0.135) (0.231) (0.198) (0.776) (0.680)
Intercept 1.793*** 1.001** 0.165 -0.270 -1.573
(0.351) (0.483) (0.481) (1.883) (1.670)
Impact of conditioning on GP consultation count (reference level = 0)
1-2 -0.237 -1.384*
(0.206) (0.794)
3-5 0.534*** -1.248
(0.206) (0.817)
6-10 0.952*** -0.203
(0.214) (0.860)
more than 10 1.977*** 1.640**
(0.270) (0.832)
lnα 0.012 1.099*** 0.489*** 3.895*** 3.307***
(0.056) (0.058) (0.075) (0.121) (0.150)
Zero-inflation parameters
zero GP consultation count 16.68*** 14.97***
(0.322) (0.722)
intercept -16.17*** -12.86***
(0.233) (0.558)
AIC 6067.9 4913.3 4480.0 1514.5 1445.4
BIC 6142.6 4988.0 4589.2 1589.2 1554.6
§ Age measured in decades from an origin of 50. Standard errors in parentheses. Sample size N   2,314.
Reference categories:  degree-level education; ¶ England. Statistical significance: * = 10%, ** = 5%, *** =
1%.
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Table 1 shows a significant predictive role of allostatic load for GP consultations, implying
an expected increase of e0.21  1   23% in GP consultations five years after a one standard
deviation increase in allostatic load. In models for OP and IP that condition on the GP
count, there is no further statistically significant direct impact of allostatic load, so the effect
of allostatic load is primarily channeled through the increased engagement with primary
healthcare. The marginal models of OP and IP that do not condition on the GP count
have highly significant coefficients of 0.129 and 0.555, implying total five-year impacts of a
standard deviation increase in allostatic load as 14% for OP consultations and, much higher,
at 74% for IP days. The statistical dependence between the GP count and the OP and IP
counts is confirmed by the large significant coefficients for the GP variables in the conditional
OP and IP models, and the much higher AIC and BIC statistics for the models that do not
condition on GP visits.
Specifying higher order polynomials of allostatic load (second or third order) revealed no
significant nonlinearity in any of our model specifications (P -values between 0.205 and 0.985).
To determine whether the predictive role of allostatic load varies by age and gender, we tested
the relevant interaction terms in all model specifications for GP, OP and IP utilisation counts.
There were no significant differences: P -values for the interactions of allostatic load with
gender range between 0.105 and 0.830 across the different models; those for age interactions
range between 0.155 and 0.699.19
We now consider the sub-sample of individuals with elevated levels of allostatic load
at baseline (defined as at least one standard deviation above the mean), and examine the
expected savings in future healthcare resource utilisation and cost generated by that group,
which would result under a counterfactual where each had their allostatic load lowered by
one standard deviation. Since we are interested in the effect of variations in allostatic load
on the aggregate burden of treatment within this part of the population, it is appropriate to
examine the mean of the counterfactual effect over all members of the group, rather than the
effect calculated for an ‘average’ individual to represent the group.20 To do this, we use the
19As a further sensitivity check, we also re-estimated our preferred utilisation models using age-gender
dummies instead of age polynomials; we still failed to reject the null hypothesis of linearity in allostatic load
(P -values ranging from 0.142 to 0.893).
20Of course, this is a quantitative summary of the importance of allostatic load as an indicator of the risk
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following sequential Monte Carlo simulation, conditional on the observed baseline covariates,
where r   1 . . .R indexes pseudo-random replication sequences.21
(i) For each member i of the group with elevated allostatic load at baseline, construct
counterfactual covariate vectors Xi identical to the observed X i, but with the allostatic
load variable reduced by 1 standard deviation unit for each individual.
(ii) At each replication r, draw a pair of pseudo-random counts Y GPir , Y
GP
ir from the
conditional distributions PrY GPi SX i and PrY GPi SXi , derived from the fitted model for
GP consultations (column (1), Table 1). The same underlying set of pseudo-random numbers
is used to generate both Y GPir and Y
GP
ir .
(iii) At each replication r, use Y GPir to construct a vector Zir containing the five ad-
ditional dummy variables representing GP utilisation which appear in the conditional OP
and IP models (columns (3) and (5) of Table 1), and construct an extended covariate vector
Xir   X i,Zir. Then evaluate PrY OPi SXir and PrY IPi SXir for each individual, using
the fitted conditional models for OP and IP consultation counts, and draw pseudo-random
Y OPir and Y
IP
ir from those distributions.
(iv) Repeat step (iii), substituting the counterfactual Xi , Y
GP
ir for X i, Y
GP
ir but re-
using the same underlying pseudo-random numbers, to generate counterfactual outcomes
Y OPir , Y
IP
ir .
(v) Compute any means and probabilities of positive counts for Y GP , Y OP , Y IP over all
individuals i in the elevated-allostatic load group and all R replications. For each utilisation
count Y , average marginal effects are expressed as % differences between base and counterfac-
tual outcomes. For mean counts, they are computed as 100 PiPrY irYir~PiPr Yir, while
the % difference at the extensive margin is 100  PiPr1Y ir A 01Yir A 0~PiPr 1Yir A
of future excess costs, not a policy simulation. Any feasible public health intervention would have a much
more complex outcome than an immediate one standard deviation reduction in allostatic load. Note also
that, unlike a marginal effect for an ‘average individual’, these average effects are not generally symmetric
across groups – for example, the effect of transforming those observed to be male into counterfactual females
is not the negative of the effect of transforming sampled females into counterfactual males.
21It is possible to construct confidence intervals for simulated resource utilisation and cost, using bootstrap
resampling. This requires repetition of the model estimation and utilisation/cost simulation and is very
intensive in computer time. For this reason, we report confidence intervals only for the key estimates of the
effects of allostatic load in Tables 2 and 4.
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0 and 1. is the indicator function.
The results are shown in Table 2. Confidence intervals are wider for the OP and IP
impacts, because OP and IP consultations are relatively uncommon and because the esti-
mates relate to averages over a small subsample of individuals with allostatic load at least
one standard deviation above mean at baseline.22 Allostatic load proves to be a very strong
predictor of future healthcare demand, suggesting potential for a substantial reduction in
resource usage if effective interventions could be targeted on those with high allostatic load.
Most of the effect is at the intensive rather than extensive margin, with the proportion of
individuals calling on GP, OP and IP resources reduced much less proportionately than is
the mean consultation count. A 1σ reduction among the group with high allostatic load is
predicted to reduce GP and OP consultations by 19% and 12% respectively. Results for the
more costly IP resource are stronger still, with a 1σ reduction in allostatic load reducing ex-
pected future resource usage by over 40%. Allostatic load is a particularly effective predictor
for relatively serious conditions requiring hospital stays.
Table 2: Estimated effects of a one standard deviation reduction in allostatic load on expected
future resource utilisation counts among individuals with elevated allostatic load at baseline
Mean Marginal effect Base Marginal effect at
Service base [90% confidence proportion extensive margin
type count interval]§ positive [90% confidence interval]§
GP consultations 3.12 -18.9 0.75 -5.4%
[-27.8%, -15.6%] [-7.9%, -4.4%]
OP consultations 1.80 -12.4 0.46 -4.9%
[-24.4%, -2.4%] [-9.3%, -1.1%]
IP days 0.94 -43.5 0.07 -15.4%
[-63.0%, 10.2%] [-44.2%, 4.5%]
 Predicted mean count and probability of positive utilisation averaged over the 359 individuals with allostatic load at least
1σ above mean at baseline (15.5% sample proportion).  Percentage difference in the proportion with positive utilisation
within the high-allostatic load group. § Nonparametric bootstrap confidence intervals, with both model estimation and
utilisation simulation repeated at each of 277 bootstrap replications.
22Our use of 90% confidence intervals is motivated by a belief that the relevant alternative hypothesis is 1-
sided rather than 2-sided – it is implausible to suggest that worsening health reduces the expected healthcare
burden. Thus the lower limit of the 90% confidence interval can be interpreted either as part of a 2-sided
90% interval, or more appropriately as a 95% 1-sided confidence limit on the magnitude of the effect. The
bootstrap calculation is burdensome because it involves simulation within simulation. We attempted 300
bootstrap replications; 23 were lost due to non-convergence of one or more of the re-estimated models. We
have not attempted to modify specifications or explore alternative starting values for the ML optimisation
in those 23 cases.
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5 Costs
Our procedure for inferring costs necessarily differs between the GP, OP and IP resource
types because of differences in the detail available from NHS reference cost statistics. In
Britain, GPs are independent contractors to the NHS and there is consequently less detailed
administrative data relating to the treatment profile of their caseloads and the corresponding
costs than there is for hospital treatments. For GP consultations we have used a single
average unit cost figure of c¯GP   £66.20 per consultation (Curtis and Burns, 2017). To exploit
this unit cost figure, we assume that the unobserved true individual-specific average cost of
a GP consultation may vary between individuals, but is uncorrelated with the number of
consultations, conditional on personal characteristics, implying that the conditional expected
cost incurred for individual i is:
E CGPi SXGPi    c¯GPE Y GPi SXGPi  (4)
For OP cases in each treatment category j, there is a unit cost c¯OP j and aggregate
number of treatment episodes nOP j, from which category proportions can be constructed
as piOP j   nOP j~PnOP . By the same reasoning as before, we arrive at a conclusion that
E COPi SXOPir    c¯OPE Y OPi SXOPi , where c¯OP   Pj piOP jc¯OP j and XOPir is the covariate
vector in the OP consultation model, constructed at replication r using Y GPir .
Table 3 summarises the cost simulations for each of nine hypothetical variations: a 1σ
reduction in allostatic load for all those who are at least 1σ above the mean; an increase
in age of 10 years for all members of each of five baseline age groups; changing gender for
the two gender groups in turn; increasing educational attainment by one category for the
unqualified and the intermediate group; and a universal 10% increase in equivalised income.
This analysis allows us to interpret the results by comparing the predicted impact of a
reduced allostatic load with demographic and socioeconomic differences in healthcare costs.
The expected GP costs in Table 3 are particularly high for the group with elevated
allostatic load compared to all the comparator demographic and socioeconomic groups. For
example, the mean base cost for those with high allostatic load is about £207, exceeding
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even the GP costs incurred for the over-75 age group. A 1σ reduction in baseline allostatic
load for those with elevated values would reduce GP costs by almost one-fifth, holding other
characteristics constant. This almost four times larger in magnitude than the proportional
increase in the GP costs from an additional 10 years of age among the oldest group, and is
only exceeded by the proportional difference in mean GP costs between men and women.
The mean OP costs in Table 3 are uniformly higher than GP costs across the set of
illustrative baseline population groups. Predicted mean OP costs for the group with elevated
allostatic load (£295) exceed those of every other group except for the over-75s (£420). For
the former group, a 1σ reduction in allostatic load reduces predicted mean OP costs by over
12%, which is larger in magnitude than the proportionate impacts of differences in education
and income, but smaller than the effects of gender or of ageing by ten years among the over-45
population.
Table 3: Personal characteristics and annual GP and OP costs five years later
GP consultations OP consultations
Base sample and Mean base % change Mean base % change
hypothetical variation cost in cost cost in cost
High allostatic load - 1σ £207 -18.9 £295 -12.4
Age 16-29 + 10 years £128 -5.1 £168 -3.5
Age 30-44 + 10 years £133 -2.4 £173 5.2
Age 45-59 + 10 years £140 1.4 £194 16.8
Age 60-74 + 10 years £166 4.1 £266 37.2
75 and over + 10 years £197 5.2 £420 62.4
Males   female £119 26.9 £171 32.6
Females   male £162 -23.2 £231 -28.5
No qualifications   intermediate £179 -7.4 £251 7.1
Intermediate   degree £141 -1.6 £208 -11.6
All incomes + 10% £143 -1.3 £205 -1.0
Sample sizes: high allostatic load: 359; age 16-29: 239; age 30-44: 740; age 45-59: 823; age 60-74: 444; age over
75: 68; males: 1,018; females: 1,296; no qualifications: 345; intermediate qualifications: 945; all incomes: 2,314.
 Predicted costs are proportional to predicted utilisation for GP and OP services, so the % change in cost is
identical to the corresponding figure in Table 2
For IP cases, we have much richer cost and caseload information (section 2.3). For
each treatment category, we observe caseload broken down by age group and (separately)
by gender. We also observe average unit cost and upper and lower quartiles of unit cost
for normal length episodes. Treatment categories are further separated into elective (E),
non-elective long stay (NEL) and non-elective short stay defined as 2 days or less (NES). We
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treat these types as separate categories, exploiting the fact that caseload, unit cost and mean
length of stay (but not other episode characteristics) are broken down by type of episode.
We follow NHS reporting practices which give episode unit costs for durations within
a specified limit (“trim point”) and a lower unit cost for “excess stays” – the part of any
episode beyond the trim point. So, for the jth treatment category, the episode-specific cost
function is:
cjY    θ1j minY,Tj  θ2j max0, Tj  Y  (5)
where Tj is the trim point, θ1j is the per diem unit cost for “inlier” episodes completed within
the normal time and θ2j is the per diem unit cost for excess days.
To incorporate the unit cost information, in each replication of the Monte Carlo simula-
tion outlined in section 4, we construct an individual-specific probability of each treatment
type, conditional on the simulated treatment duration and observed characteristics of each
individual. Those probabilities are used to calculate the conditional expected treatment cost,
which is then averaged over the 250 Monte Carlo replications. The procedure is necessar-
ily complex and is set out in detail in Appendix 2. Table 4 gives two alternative sets of
cost estimates. The first (columns 1 and 2) uses only the simulated IP duration to tailor
treatment type probabilities to individuals; the second (columns 3 and 4) uses duration, age
group and gender to tailor the treatment probabilities. Perhaps surprisingly, the additional
use of demographic information changes the simulated costs rather little.
The predictive power of allostatic load is again clear. The subgroup with allostatic load
more than 1σ above the mean are predicted to generate a mean total cost of just over
£320 five years later (compared to a mean prediction of approximately £175 for the whole
sample). If allostatic load were hypothetically reduced by 1σ for each member of this group,
the implication would be a reduction of almost a quarter in their future IP costs: roughly
comparable to ten years’ ageing in middle age and early old age.23
The second panel of Table 4 combines the results for GP, OP and IP costs to give a picture
of the overall influences on total direct treatment costs and confirms the major influence of
23The estimated % change in cost for the 45-59, 60-74 and over 75 age groups (16.3%, 28.3% and 52.4%
respectively), weighted by group sample numbers, average to 22%.
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allostatic load. Those with elevated biomarkers at baseline are predicted to generate a
mean total cost of £823 five years later. If allostatic load were hypothetically reduced by
one standard deviation for each member of this group, combined future GP, OP and IP
costs are predicted to be reduced by 18%, so there is clear scope for an effectively targeted
intervention to curtail future healthcare costs significantly. This projected % reduction in
total cost is broadly comparable with the predicted cost differences stemming from ageing
(19% weighted average effect of an additional 10 years for the 45-59, 60-74 and 75+ groups),
gender (approximately 22%) and one category of education (approximately 17%).
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Table 4: Personal characteristics and expected IP costs and total costs five years later
Statistical allocation on ...
duration only duration+age+gender
Mean % change Mean % change
Base group and base cost in cost base cost in cost
hypothetical variation (1) (2) (3) (4)
Conditional mean IP costs
High allostatic load - 1σ £321 -23.2 £323 -23.8
[90% confidence interval]§ [-49.2, 7.5]
Age 16-29 + 10 years £142 -17.4 £136 -15.9
Age 30-44 + 10 years £134 2.4 £125 7.9
Age 45-59 + 10 years £163 11.7 £162 16.3
Age 60-74 + 10 years £243 30.4 £258 28.3
75 and over + 10 years £450 55.6 £442 52.4
Males   female £160 10.0 £163 6.1
Females   male £187 -11.3 £182 -8.2
No qualifications   intermediate £354 -37.1 £358 -35.3
Intermediate   degree £179 -36.6 £175 -34.5
All incomes + 10% £175 -0.8 £174 -0.1
Conditional mean total (GP+OP+IP) costs
High allostatic load - 1σ £823 -18.2 £825 -18.5
[90% confidence interval]§ [-28.5, -8.7]
Age 16-29 + 10 years £438 -8.5 £432 -7.9
Age 30-44 + 10 years £439 2.1 £430 3.6
Age 45-59 + 10 years £496 10.8 £495 12.2
Age 60-74 + 10 years £675 26.6 £690 25.9
75 and over + 10 years £1,067 49.0 £1,059 47.6
Males   female £450 23.1 £453 21.6
Females   male £581 -21.5 £576 -20.6
No qualifications   intermediate £784 -16.2 £788 -15.5
Intermediate   degree £529 -17.4 £524 -16.5
All incomes + 10% £523 -1.0 £522 -0.8
§ Nonparametric bootstrap confidence intervals, with both model estimation and utilisation simulation repeated
at each of 277 bootstrap replications.
6 Limitations and robustness
Our analysis has significant limitations, some of which are inherent in any research in this
area. Like any survey-based analysis, estimates are subject to possible distortion from various
types of general and item non-response, particularly related to the biomarker data used to
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measure baseline health objectively. Moreover, any attempt to attach costs to healthcare
utilisation involves accounting and recording errors inherent in the available reference cost
data, which are averages across groups of cases rather than true individual-specific costs and
exclude some cost elements (such as most community health services).
Our methodology of statistical cost allocation rests on assumptions that may seem strong
at first sight, although we would argue that they are more innocent than they appear. In
estimating IP costs, we assume an individual’s reported number of days in the hospital (that
is, each admission) stem from a single episode. It should be noted here that the payment
by results reimbursement scheme, adopted by the NHS since 2004, provides no financial
incentive for healthcare providers to increase the number of episodes per admission, aiming
to promote both efficiency and the accuracy of the initial diagnosis. According to NHS
statistics, the vast majority of the patient spells (a continuous period of time spent as a
patient within a trust, which is equivalent to an admission) have only one episode, while
there is only a tiny proportion of admissions with three or more episodes (Department of
Health, 2012). Note also that the expected total cost over multiple episodes is the sum of
the expected cost of each, so multiple episodes have no inherent impact on expected total
cost, only indirectly through our use of duration in the calculation of individual-specific
probabilities of alternative disease/treatment types.
The outcomes that we study are necessarily limited. We look at healthcare utilisation five
years after the baseline as a single snapshot, rather than a long-term sequence of outcomes,
and we can say nothing directly about the duration of those impacts on the public healthcare
system. Since we do not have biomarker measurement repeated over time, we do not observe
change in biomarkers and can therefore say nothing definite about the optimal frequency of
measurement within a real-world screening programme. Our cost analysis is a distributional
analysis in the sense that it assigns cost to the individual whose ill-health generates the need
for treatment. That analysis contributes to our understanding of the processes leading to
escalating health costs, but it does not tell us about the distribution of the financial burden
of those costs across the population, which depends on the redistributive nature of the tax
system used to fund public healthcare costs.
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We carried out sensitivity checks to determine whether our results are sensitive to our use
of English NHS reference cost data to the whole sample, which includes individual’s resident
in Wales and Scotland. Restricting the analysis to English residents (93% of our full sample)
gives results that are practically identical to those for the full GB sample both in terms of
model estimates (Appendix Table A4) and cost implications (Table A5). We also assessed
sensitivity to the role of medications by repeating our analysis excluding the few individuals
(4% of the sample) who, at baseline, were taking medication for high blood pressure, cardio-
vascular conditions, diabetes or respiratory conditions.24 The model estimates (Table A6)
and cost simulation results (Table A5) are very close to our primary results.
7 Discussion and conclusions
In this paper we have adopted a forward-looking approach to explore the predictive power
of biomarkers and other personal characteristics for the utilisation of health services and
associated costs, five years later. To the best of our knowledge, it is the first analysis of
its kind. Using data from UKHLS on a group of individuals with no history of diagnosed
health conditions, we find that a biomarker-based approximation to allostatic load reflecting
pre-diagnosed and pre-symptomatic pathways is a powerful predictor of the future burden of
service utilisation for the primary and hospital healthcare systems. Combining the prediction
models with healthcare cost data for England, we have quantified the excess healthcare
costs generated by those individuals with elevated biomarkers at baseline. To achieve this,
we developed a simulation-based method of assigning administrative cost estimates to the
service utilisation levels predicted by count data models, incorporating both duration and
demographic characteristics to personalise the assignment in the case of inpatient treatment
episodes.
Overall, we found that those with elevated biomarkers are predicted to generate a mean
annual total healthcare cost (GP, OP consultations and IP days) of £823 five years later.
A standard deviation reduction in allostatic load for each member of this group resulted
24These individuals reported taking medication despite having reported no such diagnosed conditions. It
is not certain which of the two reports is erroneous in any given case.
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in an 18% reduction in predicted total costs, with the largest impact for hospital inpatient
treatment. These results suggest that there is clear scope for interventions targeted effectively
on those with elevated biomarkers to reduce future health care costs significantly – if such
interventions can be designed. The magnitude of the effects of allostatic load on caseloads
and costs is broadly comparable with the substantial estimated influence we found for age
and education. Although the main focus of our paper is not the socioeconomic gradient in
healthcare and costs, our results extend previous evidence of the impact of education on
health (Conti et al., 2010) to healthcare utilisation and costs.
The predictive power of the biomarker-based health measures gives a possible basis for
sophisticated tailoring of preventive interventions. Our findings suggest that effective tar-
geting reflecting the biological pattern of risk using biomarker data could identify better
the population groups with highest potential future healthcare needs and costs. A mea-
sure similar to our allostatic load proxy could be constructed from information gathered in
screening check-up programmes, like the NHS England Health Checks and similar programs
in other countries including Australia, Germany, the Netherlands and Japan (OECD, 2019;
Schu¨lein et al., 2017). Recent technical developments have expanded the options for ob-
taining biomarkers at the population level. As an alternative to conventional venepuncture,
dried blood spot (DBS) sampling (drops of whole blood collected on filter paper from a
simple finger prick) offers a minimally invasive method for sampling blood, at a significantly
lower collection cost (Martial et al., 2016; McDade et al., 2007). Recent evidence alleviates
concerns over the validity of DBS-derived biomarkers (Samuelsson et al., 2015), suggesting
that the DBS method has become an effective way to implement blood-based screening tests
on a large scale in practice. We hope that technical improvements and evidence of the kind
presented here may contribute to the development of these programmes to improve their
cost-effectiveness.
There is a continuing debate on capitation-based payments that are currently used to
allocate budgets to GPs in a number of countries (Brilleman et al., 2014; Chambers, 1998;
Sibley and Glazier, 2012; Shepherd, 2017). A potential policy application of our findings is
in refining the design of these systems by reorienting the capitation formula to match more
26
Jo
urn
al 
Pr
-pr
oo
f
closely patient level morbidity data and other individual characteristics (Shepherd, 2017).
This offers the prospect of improved allocation of resources and better health outcomes by
reducing incentives for health providers to “skim the cream” from the patient population by
selecting patient sub-groups with lower expected future healthcare costs.
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Appendix 1: Additional Figures and Tables
Figure A1: Distribution of the number of GP consultations in the preceding 12 months by
age
Figure A2: Distribution of the number of OP consultations in the preceding 12 months by
age
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Table A2: Comparison of OP and IP utilisation counts in UKHLS with administrative data
Administrative data UKHLS mean 95% CI
Outpatient and day-patient cases
England (age 15+) 1.667 1.600 1.561; 1.638
Scotland (age 15+) 1.726 1.520 1.404; 1.636
Number of inpatient days
England (age 15+) 0.644 0.706 0.638; 0.775
OP rates are based on administrative data, extracted from national schedules of reference costs
NHS Improvement (2017) and Scottish Health Service Costs (ISD Scotland, 2017) for England
and Scotland, respectively. Administrative data on IP days for England are extracted from NHS
Digital (2017). UKHLS means for OP consultations are based on imputations from grouped NB
models estimated separately for England and Scotland using the UKHLS wave 7 data.
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Table A3: Descriptive statistics for variables used in the analysis
Standard
Variable Mean deviation
Observed at baseline
Allostatic load -0.025 0.021
Age (years) 47.74 0.294
Male 0.44 0.010
Education: degree 0.44 0.010
Education: intermediate 0.41 0.010
Education: none 0.15 0.007
ln(equivalised income) 7.40 0.014
England 0.93 0.005
Scotland 0.05 0.005
Wales 0.02 0.003
Observed five years later:
GP consultations:
None 0.32 0.010
1-2 0.40 0.010
3-5 0.19 0.008
6-10 0.06 0.005
10+ 0.03 0.004
OP consultations:
None 0.60 0.010
1-2 0.26 0.009
3-5 0.08 0.006
6-10 0.04 0.004
C 10 0.02 0.003
IP days 0.31 0.064
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Table A4: Estimated parameters for grouped negative binomial models of GP, OP and IP
utilisation: UK (n   2,314) and English (n   2,144) samples
GP model OP model IP model
Parameter UK England UK England UK England
Allostatic load 0.210 0.213 -0.030 -0.027 0.219 0.261
(0.036) (0.038) (0.055) (0.057) (0.175) (0.181)
§Age -0.053 -0.046 0.068 0.079 0.177 0.158
(0.030) (0.031) (0.045) (0.047) (0.137) (0.143)
§Age2 0.017 0.019 0.002 0.010 -0.051 -0.050
(0.016) (0.017) (0.026) (0.027) (0.072) (0.076)
Male -0.198 -0.205 -0.319 -0.325 -0.493 -0.712
(0.076) (0.079) (0.110) (0.114) (0.370) (0.386)
§Age male 0.146 0.133 0.119 0.109 -0.165 -0.237
(0.042) (0.045) (0.067) (0.069) (0.201) (0.203)
§Age2 male -0.025 -0.028 0.061 0.057 0.247 0.258
(0.025) (0.026) (0.037) (0.039) (0.111) (0.115)
No qualifications 0.092 0.052 -0.016 -0.058 1.481 1.442
(0.092) (0.094) (0.137) (0.142) (0.718) (0.718)
Intermediate 0.016 -0.004 0.112 0.089 0.745 0.718
qualifications (0.065) (0.068) (0.096) (0.099) (0.290) (0.304)
ln(income) -0.140 -0.147 -0.002 -0.007 0.101 0.104
(0.045) (0.047) (0.059) (0.061) (0.206) (0.204)
Wales 0.555 -0.365 -1.062
(0.192) (0.249) (0.590)
Scotland -0.018 -0.311 -0.405
(0.135) (0.198) (0.680)
1-2 GP consultations -0.237 -0.280 -1.384 -1.745
(0.206) (0.212) (0.794) (0.743)
3-5 GP consultations 0.534 0.483 -1.248 -1.439
(0.206) (0.211) (0.817) (0.764)
6-10 GP consultations 0.952 0.905 -0.203 -0.471
(0.214) (0.219) (0.860) (0.822)
A 10 GP consultations 1.977 1.839 1.640 1.097
(0.270) (0.277) (0.832) (0.787)
Intercept 1.793 1.859 0.165 0.255 -1.573 -1.207
(0.351) (0.363) (0.481) (0.497) (1.670) (1.671)
lnα 0.012 0.017 0.489 0.461 3.307 3.278
(0.056) (0.058) (0.075) (0.079) (0.150) (0.156)
Zero-inflation parameters
No GP consultations 16.68 17.87 14.97 14.35
(0.322) (0.431) (0.722) (0.745)
Intercept -16.17 -17.32 -12.86 -12.03
(0.233) (0.370) (0.558) (0.558)
§ Age measured in decades from 50 years. Standard errors in parentheses. Statistical significance: * = 10%, ** = 5%, *** = 1%.
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Table A5: Robustness checks: alternative estimates of total costs (GP+OP+IP)
Full sample England only No medication
Base sample Mean % change Mean % change Mean % change
and base in mean base in mean base in mean
variation cost cost cost cost cost cost
High allostatic load - 1σ £825 -18.3 £832 -19.0 £794 -18.4
Age 16-29 + 10 years £432 -7.9 £446 -8.5 £438 -8.9
Age 30-44 + 10 years £430 3.6 £432 3.4 £431 2.6
Age 45-59 + 10 years £495 12.2 £496 11.5 £496 11.4
Age 60-74 + 10 years £690 25.9 £684 25.9 £674 25.7
75 and over + 10 years £1,059 47.6 £1,079 44.3 £968 49.4
Males   female £453 21.6 £441 28.3 £439 23.4
Females   male £576 -20.6 £589 -24.4 £570 -22.0
No qualifications   intermediate £788 -15.5 £765 -13.1 £783 -19.6
Intermediate   degree £524 -16.5 £528 -14.8 £521 -18.8
All incomes +10% £522 -0.8 £524 -0.9 £510 -0.5
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Table A6: Estimated parameters for grouped negative binomial models of GP, OP and
IP utilisation: individuals on medication at baseline included (n   2,314) and excluded
(n   2,234)
GP model OP model IP model
Parameter included excluded included excluded included excluded
Allostatic load 0.210*** 0.204*** -0.030 -0.019 0.219 0.199
(0.036) (0.038) (0.055) (0.058) (0.175) (0.190)
§Age -0.053* -0.073** 0.068 0.076 0.177 0.213
(0.030) (0.031) (0.045) (0.049) (0.137) (0.154)
§Age2 0.017 0.009 0.002 0.009 -0.051 -0.045
(0.016) (0.017) (0.026) (0.028) (0.072) (0.086)
Male -0.198*** -0.200** -0.319*** -0.330*** -0.493 -0.485
(0.076) (0.078) (0.110) (0.113) (0.370) (0.380)
§Age male 0.146*** 0.174*** 0.119* 0.115 -0.165 -0.312
(0.042) (0.044) (0.067) (0.071) (0.201) (0.239)
§Age2 male -0.025 -0.014 0.061 0.064 0.247** 0.225*
(0.025) (0.026) (0.037) (0.040) (0.111) (0.116)
No qualifications 0.092 0.072 -0.016 0.006 1.481** 1.858**
(0.092) (0.095) (0.137) (0.143) (0.718) (0.789)
Intermediate 0.016 0.005 0.112 0.093 0.745** 0.978***
(0.065) (0.067) (0.096) (0.099) (0.290) (0.303)
ln(income) -0.140*** -0.151*** -0.002 0.011 0.101 0.310
(0.045) (0.046) (0.059) (0.062) (0.206) (0.189)
Wales 0.555*** 0.609*** -0.365 -0.438* -1.062* -1.379*
(0.192) (0.199) (0.249) (0.252) (0.590) (0.740)
Scotland -0.018 -0.003 -0.311 -0.312 -0.405 -1.348**
(0.135) (0.139) (0.198) (0.205) (0.680) (0.656)
1-2 GP consultations -0.237 -0.238 -1.384* -0.589
(0.206) (0.208) (0.794) (0.996)
3-5 GP consultations 0.534*** 0.527** -1.248 -0.392
(0.206) (0.207) (0.817) (1.038)
6-10 GP consultations 0.952*** 0.919*** -0.203 0.718
(0.214) (0.216) (0.860) (1.107)
A 10 GP consultations 1.977*** 2.076*** 1.640** 2.908***
(0.270) (0.277) (0.832) (1.075)
Intercept 1.793*** 1.869*** 0.165 0.069 -1.573 -4.082**
(0.351) (0.356) (0.481) (0.499) (1.670) (1.893)
lnα 0.012 0.010 0.489*** 0.516*** 3.307*** 3.324***
(0.056) (0.058) (0.075) (0.076) (0.150) (0.154)
Zero-inflation parameters
No GP consultations 16.68*** 16.12*** 14.97*** 13.57***
(0.322) (0.325) (0.722) (0.833)
Intercept -16.17*** -15.61*** -12.86*** -11.67***
(0.233) (0.234) (0.558) (0.484)
§ Age measured in decades from 50 years. Standard errors in parentheses. Statistical significance: * = 10%, ** = 5%, *** = 1%.
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Appendix 2: Allocation of costs for inpatient days
The aim here is to construct an estimate of the individual’s expected treatment cost C,
conditional on his or her personal characteristics X. There are two cases; the simpler setting
is where we have data from administrative records on the full distribution of X conditional
on the treatment category j. This is the case if we use only age variables or only gender
variables as covariates in the IP count data model, since we the NHS administrative data
give separate age and gender breakdowns of unit cost and caseload. A more problematic
setting is where X is a vector and we only have univariate marginal distributions of a subset
of the variables in X-variable. This is relevant if we use a full range of demographic and
socioeconomic covariates in X.
Let Y be the episode duration and cjY  be the cost function (5). The probability func-
tion fY, j,X represents the distribution across IP episodes of treatment type and duration
and personal characteristics of the patient and is defined as the probability of a randomly-
selected episode being treatment type j for length of stay Y received by a person with
characteristics X. We also use f. as generic notation for any conditional or marginal dis-
tribution derived from fY, j,X, with the type of distribution defined by the argument list.
The count data model for duration in days gives a distribution hY SX which is conditional
on X but not on the treatment type which is unobserved in the UKHLS.
Write X   A,G,S, where A represents age variables, G is a gender indicator and
S is a set of socioeconomic descriptors. The difficulty here is that we observe separate
treatment-specific marginal distributions Y Sj, ASj and GSj but not their joint distribution,
and we have no information at all on the distribution of S within treatment categories. The
simplest way of using this information is to make the conditional independence assumption
Y á A á G á Sj, which implies fY, j,A,G,S   fY SjfASjfGSjfSSjfj. This is
much less restrictive than full independence, since it allows the duration, demographic and
socioeconomic composition of patient groups to be completely different in different treatment
categories.
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Under these assumptions, the conditional expectation of cost is:
EC SY   y,X   PJj 1 cjyfySjfASjfGSjfSSjfj
PJj 1 fySjfASjfGSjfSSjfj (A1)
This structure is not operational, since fSSj is unobserved. To overcome this, make the
further assumption that the weighted covariance over treatment categories between cjy
and fSSj is zero for any y and any S:
Q
j
wjcjyfSSj  Q
j
wjcjyQ
j
wjfSSj   0 (A2)
where the weight wj is:
wj  
fySjfASjfGSj
Pj fySjfASjfGSj (A3)
Assumptions (A1) and (A2) imply EC SY   y,X   Pj wjcjyfSSj~Pj wjfSSj   Pj wjcjy
and thus EC SY   y,X does not depend on S:
EC SY   y,X   PJj 1 cjyfySjfASjfGSjfj
PJj 1 fySjfASjfGSjfj (A4)
In other words, expected cost may depend on socioeconomic characteristics, but that de-
pendence disappears if we also condition on treatment duration - people with different so-
cioeconomic characteristics incur different costs only because they tend to have different IP
durations.
Overall expected cost is:
EC SX  Q
y
hySXPJj 1 cjyfySjfASjfGSjfj
PJj 1 fySjfASjfGSjfj (A5)
Exactly the same approach can be used without exploiting age and gender information,
by simply removing the terms fASjfGSj from (A5). This allows us to assess the role of
demographic characteristics in converting utilisation counts into expected costs.
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